All News

biosim.sign_.jpg

Biosimilars Match Biologic Originators in Rheumatoid Arthritis

d Jack Cush, MD

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

Read Article
labs2.jpg

Time to Risk Stratify Methotrexate Lab Monitoring?

d Jack Cush, MD

A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.

Read Article
gca vasculitis

EULAR 2023 recommendation for imaging in large vessel vasculitis

d Bella Mehta, MBBS, MS

Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease. At EULAR 2023, recommendations for imaging modalities for large vessel vasculitis were discussed. These were evidence-based recommendations adapted for practicality in clinical use.  

Read Article
Watch: IRAEs, Targeted Therapies and Survival Dr. Aurelie Najm discusses OP0270 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/501Rc4SPY1 https://t.co/Ifw93ICqwW

Links:

Dr. John Cush RheumNow ( View Tweet)
Novel drug in development, LY3361237, is a BTLA (B & T lymphocyte attenuator) agonistic antibody to treat autoimmune Dz (eg SLE) - augments immune responses by activating checkpoint inhibitory receptors (CIRs). https://t.co/3iYq9UwHww https://t.co/RwrhqRO8cm https://t.co/tl8qVIXqjc

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/kmjo3HYg4K https://t.co/PINZryXQBP

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/6OVZhkTdGc https://t.co/3VHhI7nfQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Assessing CV Risk in Inflammatory Arthritis: Which Score? Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/qlJ9iMwrip @AurelieRheumo https://t.co/Yh2siy6555

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept: is there a role before RA hits? Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy. @drdavidliew https://t.co/SPLOCjjhUt https://t.co/wkPJLz9ctg

Links:

Dr. John Cush RheumNow ( View Tweet)
ANCA-associated vasculitis: beyond therapy with rituximab? AAV is a group of multi-system autoimmune small vessel vasculitides which includes GPA, MPA and EGPA. https://t.co/eZ3mgdjrEp https://t.co/dM9B4tVgmr

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate - an old trusted friend who deserves better MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice. https://t.co/xp40KklMkA https://t.co/oVqzlQeqbe

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular2023 Coverage - SLE Panel Discussion https://t.co/pLWOqZo2aw https://t.co/itAOjgmMTl

Links:

Dr. John Cush RheumNow ( View Tweet)
AOSD: Young vs. Elderly Onset AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. https://t.co/fg5TakEvvv https://t.co/lu34gX7WTZ

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Notes from Milan Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy https://t.co/brcgGv2GHD https://t.co/zVyZkEuLy4

Links:

Dr. John Cush RheumNow ( View Tweet)
Assessing CV Risk in Inflammatory Arthritis: Which Score? Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. https://t.co/MvqkKya4vm @AurelieRheumo

Links:

Dr. John Cush RheumNow ( View Tweet)

Combining a Tyk2 inhibitor with a JAKi in RA? Dr. Janet Pope (@Janetbirdope ) weighs in on #EULAR23 abstracts. https://t.co/7fTZjvnHT3 https://t.co/o43VrWpVpI

Links:

Dr. John Cush RheumNow ( View Tweet)
A step change towards self-empowerment for people living with SLE As I reflect on my research journey, I recall several issues that still need to be addressed in the management of SLE. https://t.co/ElunbUgSGF https://t.co/YmA1YWPxVP

Links:

Dr. John Cush RheumNow ( View Tweet)
Postpartum Depression in RA Dr. Jonathan Kay discusses abstract POS0206-HPR at EULAR 2023 in Milan, Italy. https://t.co/dzUMIia8Q6 https://t.co/IjeEvz8Cab

Links:

Dr. John Cush RheumNow ( View Tweet)
The Importance of Identifying Central Pain in PsA Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy. https://t.co/5fjNTrQvNx https://t.co/E1ivkK2bFz

Links:

Dr. John Cush RheumNow ( View Tweet)
Malignancy and CV Risk in Rheumatoid Arthritis Dr. Jonathan Kay discusses OP0218, OP0219 and OP0211 at EULAR 2023 in Milan, Italy. https://t.co/o5yrbCBaCb https://t.co/qptUCGb79q

Links:

Dr. John Cush RheumNow ( View Tweet)
×